New report estimates nearly 18 million cancer survivors in the US by 2022

The number of Americans with a history of cancer, currently estimated to be 13.7 million, will grow to almost 18 million by 2022, according to a first-ever report by the American Cancer Society in collaboration with the National Cancer Institute (NCI). The report, Cancer Treatment and Survivorship Facts and Figures, and accompanying journal article published in CA: A Cancer Journal for Clinicians, used data from the NCI-funded Surveillance, Epidemiology, and End Results (SEER) Program to generate brand new estimates of cancer survivor prevalence in the U.S. The reports find that even though cancer incidence rates are decreasing, the number of cancer survivors is growing due to the aging and growth of the population, as well as improving cancer survival rates.

The growing number of cancer survivors in the U.S. makes it increasingly important to understand the unique medical and psychosocial needs of survivors and raise awareness of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship. The reports were created to highlight the challenges and opportunities to serve these survivors.

The three most common cancers among males living with a history of cancer in 2012 are prostate cancer (43%), colorectal cancer (9%), and melanoma (7%). Among women in 2012 with a history of cancer, the three most common cancers are breast (41%), uterine (8%), and colorectal (8%) cancer. In 2022, those proportions are expected to be largely unchanged.

Other selected findings:

  • Nearly one-half (45%) of cancer survivors are aged 70 years or older, while only 5% are aged younger than 40 years
  • The median age of patients at the time of cancer diagnosis is 66.
  • There are 58,510 survivors of childhood cancer living in the United States, and an additional 12,060 children will be diagnosed in 2012.
  • The majority of cancer survivors (64%) were diagnosed 5 or more years ago; 15% were diagnosed 20 or more years ago.

In addition to prevalence estimates, the reports also include information on treatment, survival, and common concerns of survivors for eleven selected cancers, as well as sections on the effects of cancer and its treatment, palliative care, long term survivorship, the benefits of healthy behaviors, and resources for cancer survivors from the American Cancer Society and other organizations.

"With this effort, we review the critical issues related to cancer treatment and survivorship," said Elizabeth R. Ward, Ph.D., national vice president of Intramural Research and senior author of the report. "Many survivors, even among those who are cancer free, must cope with the long-term effects of treatment, as well as psychological concerns such as fear of recurrence. As more people survive cancer, it is vital that health care providers are aware of the special needs of cancer patients and caregivers."

Siegel, R., DeSantis, C., Virgo, K., et al. (2012), Cancer Treatment and Survivorship Statistics, 2012. CA: A Cancer Journal for Clinicians. doi: 10.3322/caac.21149

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

News in Pictures

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/9445461331.jpg

Abbott Launches New Psoriasisanswers.com Web site

August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/399322AstraZeneca_Headquarters.jpg

AstraZeneca Headquarters, London

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/280148roche_basel.jpg

Site Roche Basel

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/390839Gehry_Novartis.jpg

Gehry building, Novartis headquarters in Basel, Switzerland

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/240209GSK_Corporate.jpg

GSK Corporate HQ

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/200324sanofi_avenits.jpg

Sanofi-aventis Group head office

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/964792Boehringer_Ingelheim_Center.jpg

Boehringer Ingelheim Center, Ingelheim, Germany

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/164840Novo_Nordisk.jpg

Novo Nordisk's corporate headquarters in Bagsværd, Denmark

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more

Be on top of World Pharma News
Want to place your Ads or News at the top of World Pharma News? Contact us now!